SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 15  - SEGMENT INFORMATION

The Company operates as a single operating segment in the research and development of innovative treatments for pancreatic cancer based on siRNAs. The Company’s CODM is its Chief Executive Officer (CEO). The CODM reviews the Company’s performance on a consolidated basis. As such, the segment’s loss is the Company’s consolidated net loss and the segment’s assets are the Company’s consolidated assets.

The CODM uses the information primarily to evaluate the Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures, tracking progress on research and development milestones, and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows the CODM to monitor the Company's performance and make strategic adjustments as needed to support its operational and financial goals.

a. Segment disclosures

The CODM reviews the Company’s results on a consolidated basis. As such, information on segment loss and significant expenses is similar to the Company’s consolidated statements of operations. The CODM is also regularly provided with information on significant ordinary-course expenses, including the following expenses. the management does not segregate its business for internal reporting.

	Year ended December 31
	2024			2023
Clinical trials and other services from R&D-related service providers	$	1,893		$	2,480
Payroll and related expenses, other than share-based compensation		2,385			1,199
Share-based compensation expenses		5,862			130
Depreciation expenses		25			45
Other segment expenses (*)		2,406			827
Operating loss		12,571			4,681
Interest income		(28	)		(153	)
Interest expense		27			-
Other financing expense, net		3,939			548
Income taxes		10			32
Net loss	$	16,519		$	5,108
Segment assets	$	2,863		$	5,256
Expenditures for segment assets		(22	)		(12	)

(*) Other segment expenses include mainly general and administrative-related expenses, such as payments to advisors and consultants, office lease expenses and maintenance, HR and legal expenses.

b. Entity-Wide disclosures

All of the Company’s long-lived assets are located in Israel.